Protalix BioTherapeutics Statistics Share Statistics Protalix BioTherapeutics has 79.61M
shares outstanding. The number of shares has increased by 8.25%
in one year.
Shares Outstanding 79.61M Shares Change (YoY) 8.25% Shares Change (QoQ) 2.02% Owned by Institutions (%) 11.29% Shares Floating 76.2M Failed to Deliver (FTD) Shares 22,125 FTD / Avg. Volume 2.34%
Short Selling Information The latest short interest is 3.33M, so 4.18% of the outstanding
shares have been sold short.
Short Interest 3.33M Short % of Shares Out 4.18% Short % of Float 4.37% Short Ratio (days to cover) 4.91
Valuation Ratios The PE ratio is 46.51 and the forward
PE ratio is 3.41.
Protalix BioTherapeutics's PEG ratio is
-0.7.
PE Ratio 46.51 Forward PE 3.41 PS Ratio 2.55 Forward PS 1.4 PB Ratio 3.16 P/FCF Ratio 18.45 PEG Ratio -0.7
Financial Ratio History Enterprise Valuation Protalix BioTherapeutics has an Enterprise Value (EV) of 122.12M.
EV / Sales 2.29 EV / EBITDA 18.73 EV / EBIT 14.08 EV / FCF 16.52
Financial Position The company has a current ratio of 2.34,
with a Debt / Equity ratio of 0.13.
Current Ratio 2.34 Quick Ratio 1.52 Debt / Equity 0.13 Debt / EBITDA 0.85 Debt / FCF 0.75 Interest Coverage 3.69
Financial Efficiency Return on Equity is 6.79% and Return on Invested Capital is 5.61%.
Return on Equity 6.79% Return on Assets 3.99% Return on Invested Capital 5.61% Revenue Per Employee $250.7K Profits Per Employee $13.77K Employee Count 213 Asset Turnover 0.73 Inventory Turnover 1.14
Taxes Income Tax 1.22M Effective Tax Rate 29.42%
Stock Price Statistics The stock price has increased by 52.38% in the
last 52 weeks. The beta is -0.21, so Protalix BioTherapeutics's
price volatility has been lower than the market average.
Beta -0.21 52-Week Price Change 52.38% 50-Day Moving Average 1.49 200-Day Moving Average 1.94 Relative Strength Index (RSI) 53.22 Average Volume (20 Days) 945,390
Income Statement In the last 12 months, Protalix BioTherapeutics had revenue of 53.4M
and earned 2.93M
in profits. Earnings per share was 0.04.
Revenue 53.4M Gross Profit 29.08M Operating Income 3.92M Net Income 2.93M EBITDA 6.52M EBIT 5.22M Earnings Per Share (EPS) 0.04
Full Income Statement Balance Sheet The company has 19.76M in cash and 5.53M in
debt, giving a net cash position of 14.23M.
Cash & Cash Equivalents 19.76M Total Debt 5.53M Net Cash 14.23M Retained Earnings -378.39M Total Assets 73.89M Working Capital 36.19M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 8.67M
and capital expenditures -1.28M, giving a free cash flow of 7.39M.
Operating Cash Flow 8.67M Capital Expenditures -1.28M Free Cash Flow 7.39M FCF Per Share 0.1
Full Cash Flow Statement Margins Gross margin is 54.46%, with operating and profit margins of 7.34% and 5.49%.
Gross Margin 54.46% Operating Margin 7.34% Pretax Margin 7.78% Profit Margin 5.49% EBITDA Margin 12.21% EBIT Margin 7.34% FCF Margin 13.84%
Dividends & Yields PLX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 2.15% FCF Yield 5.42%
Dividend Details Analyst Forecast The average price target for PLX is $15,
which is 837.5% higher than the current price. The consensus rating is "Strong Buy".
Price Target $15 Price Target Difference 837.5% Analyst Consensus Strong Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 0.74 Graham Upside -53.75%
Stock Splits The last stock split was on Dec 20, 2019. It was a
backward
split with a ratio of 1:10.
Last Split Date Dec 20, 2019 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -3.02 Piotroski F-Score 4
